On September 4, 2015, Lawrence A. Kenyon, chief operating officer and chief financial officer of Arno Therapeutics, Inc. announced that he is resigning his employment with the company, effective as of September 15, 2015, in order to accept a position with a new employer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0003 USD | +417.24% | -.--% | +200.00% |
2017 | Arno Therapeutics, Inc. Terminates Licensing Agreement with Ohio State University | CI |
2017 | Arno Therapeutics Seeks Acquisitions | CI |
1st Jan change | Capi. | |
---|---|---|
+200.00% | 14.8K | |
+8.13% | 101B | |
+8.29% | 42.63B | |
+82.32% | 29.77B | |
-11.82% | 16.14B | |
+1.39% | 14.31B | |
-12.13% | 11.55B | |
+176.65% | 10.53B | |
+6.74% | 9.2B | |
-55.52% | 8.98B |
- Stock Market
- Equities
- ARNI Stock
- News Arno Therapeutics, Inc.
- Arno Therapeutics, Inc. Announces Resignation of Lawrence A. Kenyon as Chief Operating Officer and Chief Financial Officer, Effective September 15, 2015